Key Takeaways The FDA has approved zanidatamab (Ziihera®) as a first treatment for patients newly diagnosed with HER2-positive advanced cancers of the esophagus, gastroesophageal junction, and stomach ...

How are new targeted therapies for specific genetic mutations improving lung cancer treatment? We are getting new targeted therapies approved every year for genes that were long thought to be ...

Thoracic oncologist Kathryn Arbour, MD, led the Phase 1/2 clinical trial of daraxonrasib at MSK for metastatic lung cancer. The drug was approved by the FDA for pancreatic cancer in August 2026 and Dr ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

Memorial Sloan Kettering Cancer Center (MSK) has again been recognized among the nation’s very best, earning the distinction as the top cancer center in the Northeast and in the New York metropolitan ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

For people living with advanced triple-negative breast cancer (TNBC), a newly approved treatment may offer more time and a better quality of life. TNBC makes up about 10% to 20% of all breast cancers, ...

Memorial Sloan Kettering Cancer Center today announced that Shakeeb Akhter has joined MSK as its new Chief Digital Officer.

MSK gastrointestinal medical oncologist Dr. Wungki Park led the early phase clinical trial of daraxonrasib for people with metastatic pancreatic cancer that had stopped responding to chemotherapy.

MSK gastrointestinal medical oncologist Eileen O'Reilly, MD (left), led a very promising early phase clinical trial of the targeted RAS therapy daraxonrasib for people facing pancreatic cancer.

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment, MSK ...